Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8

Pigment Cell Research

Volumn 19, Issue 5, 2006, Pages 395-405

  Melnikova, Vladislava O ^a   Bar Eli, Menashe ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Angiogenesis; Fully human antibodies; Interleukin 8; MCAM MUC18; Melanoma; Metastasis

Indexed keywords

ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; CD146 ANTIGEN; CELL ADHESION MOLECULE; CELL SURFACE PROTEIN; CHEMOKINE; DACARBAZINE; IMMUNOGLOBULIN G; INTERLEUKIN 8 ANTIBODY; NEUTRALIZING ANTIBODY; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTIBODY DETECTION; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CELL ADHESION; CHEMOTHERAPY; DISEASE COURSE; GENE OVEREXPRESSION; IMMUNE ADHERENCE; IMMUNOTHERAPY; IN VIVO STUDY; MELANOMA; METASTASIS; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD146; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-8; MELANOMA;

ANIMALIA;

EID: 33748301967     PISSN: 08935785     EISSN: 16000749     Source Type: Journal    
DOI: 10.1111/j.1600-0749.2006.00331.x     Document Type: Review

References (81)

1. Addison, C.L, Daniel, T.O., Burdick, M.D., Liu, H., Ehlert, J.E., Xue, Y.Y., Buechi, L., Walz, A., Richmond, A., and Strieter, R.M. (2000). The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J. Immunol. 165, 5269-5277.
2. FAK. J. Biol. Chem. 273, 26852-26856.
3. Atkins, M.B. (2006). Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin. Cancer. Res. 12 (Suppl.), 2353s-2358s.
4. Atkins, M.B., Elder, D.E., Essner, R. et al. (2006). Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin. Cancer. Res. 12 (Suppl.), 2291s-2296s.
5. Balch, C.M., Buzaid AC, Soong SJ et al. (2001a). Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19, 3635-3648.
6. Balch, C.M., Soong, S.J., Gershenwald, J.E. et al. (2001b). Prognostic factors analysis of 17 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 19, 3622-34.
7. Bani, M.R., Rak, J., Adachi, D., Wiltshire, R., Trent, J.M., Kerbel, R.S., and Ben-David Y. (1996). Multiple features of advanced melanoma recapitulated in tumorigenic variants of early stage (radial growth phase) human melanoma cell lines: evidence for a dominant phenotype. Cancer Res. 56, 3075-3086.
8. Bar-Eli, M. (1999). Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology, 67, 12-18.
9. Berger, A.J., Davis, D.W., Tellez, C., Prieto, V.G., Gershenwald, J.E., Johnson, M.M., Rimm, D.L., and Bar-Eli, M. (2005). Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res. 65, 11185-11192.
10. Bevona, C., and Sober, A.J. (2002). Melanoma incidence trends. Dermatol. Clin. 20, 589-595.
11. Burkhardt, M., Mayordomo, E., Winzer, K.J. et al. (2006). Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J. Clin. Pathol. 59, 403-409.
12. Chuntharapai, A., and Kim, K.J. (1995). Regulation of the expression of IL-8 receptor A/B by IL-8: possible functions of each receptor. J. Immunol. 155, 2587-2594.
13. Denton, K.J., Streich, J., Gatter, K.C., and Harris, A.L. (1992). A study of adhesion molecules as markers of progression in malignant melanoma. J. Pathol. 167, 187-191.
14. Haass, N.K., Smalley, K.S., Li, L., and Herlyn, M. (2005). Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res. 18, 150-159.
15. Hersey, P. (2003). Adjuvant therapy for high-risk primary and resected metastatic melanoma. Intern. Med. J. 33, 33-43.
16. Holzmann, B., Brocker, E.B., Lehmann, J.M., Ruiter, D.J., Sorg, C., Riethmuller, G., and Johnson, J.P. (1987). Tumor progression in human melanoma: five stages defined by their antigenic phenotypes. Int. J. Cancer 39, 466-471.
17. Horuk, R., Chitnis, C.E., Darbonne, W.C., Colby, T.J., Rybicki, A., Hadley, T.J., and Miller, L.H. (1993). A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science 261, 1182-1184.
18. Howe, H.L., Wingo, P.A., Thun, M.J., Ries, L.A., Rosenberg, H.M., Feigal, E.G., and Edwards, B.K. (2001). Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J. Natl Cancer Inst. 93, 824-842.
19. Hsu, M.Y., Wheelock, M.J., Johnson, K.R., and Herlyn, M. (1996). Shifts in cadherin profiles between human normal melanocytes and melanomas. J. Investig. Dermatol. Symp. Proc. 1, 188-194.
20. Hsu, M.Y., Meier, F.E., Nesbit, M., Hsu, J.Y., Van Belle, P., Elder, D.E., and Herlyn, M. (2000). E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and downregulates expression of invasion-related adhesion receptors. Am. J. Pathol. 156, 1515-1525.
21. Huang, S., Jean, D., Luca, M., Tainsky, M.A., and Bar-Eli, M. (1998). Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J. 17, 4358-4369.
22. Huang, S., DeGuzman, A., Bucana, C.D., and Fidler, I.J. (2000). Level of interleukin-8 expression by metastatic human melanoma cells directly correlates with constitutive NF-kappaB activity. Cytokines Cell. Mol. Ther. 6, 9-17.
23. Huang, S., Mills, L., Mian, B., Tellez, C., McCarty, M., Yang, X.-D., Gudas, J.M., and Bar-Eli, M. (2002). Fully humanized neutralizaing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am. J. Pathol., 161, 125-134.
24. Jean, D., Gershenwald, J.E., Huang, S., Luca, M., Hudson, M.J., Tainsky, M.A., and Bar-Eli, M. (1998). Loss of AP-2 results in upregulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J. Biol. Chem. 273, 16501-16508.
25. Johnson JP. (1999). Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev. 18, 345-357.
26. Johnson, J.P., Bar-Eli, M., Jansen, B., and Markhof, E. (1997). Melanoma progression-associated glycoprotein MUC18/MCAM mediates homotypic cell adhesion through interaction with a heterophilic ligand. Int. J. Cancer 73, 769-774.
27. Juliano, R.L., and Varner, J.A. (1993). Adhesion molecules in cancer: the role of integrins. Curr. Opin. Cell. Biol. 5, 812-818.
28. Kirkwood, J.M., Moschos, S., and Wang, W. (2006). Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin. Cancer. Res. 12 (Suppl.), 2331s-2336s.
29. Koch, A.E., Polverini, P.J., Kunkel, S.L., Harlow, L.A., DiPietro, L.A., Elner, V.M., Elner, S.G., and Strieter, R.M. (1992). Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258, 1798-1801.
30. Koh, H.K. (1991). Cutaneous melanoma. N. Engl. J. Med. 325, 171-182.
31. Kraus, A., Masat, L., and Johnson, J.P. (1997). Analysis of the expression of intercellular adhesion molecule-1 and MUC18 on benign and malignant melanocytic lesions using monoclonal antibodies directed against distinct epitopes and recognizing denatured, non-glycosylated antigen. Melanoma. Res. 7s, 75-81.
32. Kristiansen, G., Pilarsky, C., Wissmann, C. et al. (2005). Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J. Pathol. 205, 359-76.
33. Kunz, M., Goebeler, M., Brocker, E.B., and Gillitzer, R. (2000). IL-8 mRNA expression in primary malignant melanoma mRNA in situ hybridization: sensitivity, specificity, and evaluation of data. J. Pathol. 192, 413-415.
34. Lehmann, J.M., Holzmann, B., Breitbart, E.W., Schmiegelow, P., Riethmuller, G., and Johnson, J.P. (1987). Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76 000. Cancer Res. 47, 841-845.
35. Lehmann, J.M., Riethmuller, G., and Johnson, J.P. (1989). MUC18, a marker of tumor progression in human melanoma shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc. Natl Acad. Sci. USA 86, 9891-9895.
36. Leslie, M., and Bar-Eli, M. (2005). Regulation of gene expression in melanoma: new approaches for treatment. J. Cell. Biochem. 94, 25-38.
37. Lev, D.C., Ruiz, M., Mills, L., McGary, E.C., Price, J.E., and Bar-Eli, M. (2003). Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol. Cancer. Ther. 8, 753-763.
38. Lev, D.C., Onn, A., Melinkova, V.O., Miller, C., Stone, V., Ruiz, M., McGary, E.C., Ananthaswamy, H.N., Price, J.E., and Bar-Eli, M. (2004). Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J. Clin. Oncol. 22, 2092-2100.
39. Li, G., Satyamoorthy, K., and Herlyn, M. (2001). N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res. 61, 3819-3825.
40. Liu, G., Zhang, F., Lee, J., and Dong, Z. (2005). Selective induction of interleukin-8 expression in metastatic melanoma cells by transforming growth factor-beta1. Cytokine 31, 241-249.
41. Luca, M., Hunt, B., Bucana, C.D., Johnson, J.P., Fidler, I.J., and Bar-Eli, M. (1993). Direct correlation between MUC18 expression and metastatic potential of human melanoma cells. Melanoma Res. 3, 35-41.
42. Luca, M., Huang, S., Gershenwald, J.E., Singh, R.K., Reich, R., and Bar-Eli, M. (1997). Expression of interleukin-8 by human melanoma cells upregulates MMP-2 activity and increases tumor growth and metastasis. Am. J. Pathol. 151, 1105-1113.
43. McMasters, K.M., and Swetter, S.M. (2003). Current management of melanoma: Benefits of surgical staging and adjuvant therapy. J. Surg. Oncol. 82, 209-216.
44. Mendez, M.J., Green, L.L., Corvalan, J.R. et al. (1997) Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat. Genet. 15, 146-150.
45. Miller, M.D., and Krangel, M.S. (1992). Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. Crit. Rev. Immunol. 12, 17-46.
46. Mills, L., Tellez, C., Huang, S., Baker, C., McCarty, M., Green, L., Gudas, J.M., Feng, X., and Bar-Eli, M. (2002). Fully human anti-MCAM/MUC18 inhibits tumor growth and metastasis of human melanoma. Cancer Res. 62, 5106-5114.
47. Moser, B., Barella, L., Mattei, S., Schumacher, C., Boulay, F., Colombo, M.P., and Baggiolini, M. (1993). Expression of transcripts for two interleukin 8 receptors in human phagocytes, lymphocytes and melanoma cells. Biochem. J. 294, 285-292.
48. Natali, P.G., Hemby, C.V., Felding-Habermann, B., Liang B., Nicotra, M.R., Di Filippo, F., Giannarelli, D., Temponi, M., and Ferrone, S. (1997). Clinical significance of alpha(v)beta3 integrin and intercelluar adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res. 57, 1554-1560.
49. Nurnberg, W., Tobias, D., Otto, F., Henz, B.M., and Schadendorf, D. (1999). Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J. Pathol. 189, 546-551.
50. Pacifico, M.D., Grover R., Richman, P.I., Daley F.M., Buffa, F., and Wilson, G.D. (2005). Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker. Plast. Reconstr. Surg. 115, 367-375.
51. Patel, P.S., Varney, M.L., Dave, B.J., and Singh, R.K. (2002). Regulation of constitutive and induced NF-kappaB activation in malignant melanoma cells by capsaicin modulates interleukin-8 production and cell proliferation. J. Interferon Cytokine Res. 22, 427-435.
52. Rummel, M.M., Sers, C., and Johnson, J.P. (1996). Phorbol ester and cyclic AMP-mediated regulation of the melanoma-associated cell adhesion molecule MUC18/MCAM. Cancer Res., 56, 2218-2223.
53. Rutberg, S.E., Goldstein, I.M., Yang, Y.M., Stackpole, C.W., and Ronai, Z. (1994). Expression and transcriptional activity of AP-1, CRE, and URE binding proteins in B16 mouse melanoma subclones. Mol. Carcinog., 2, 82-87.
54. Sandig, M., Voura, E.B., Kalnins, V.I., and Siu, C.H. (1997). Role of cadherins in the transendothelial migration of melanoma cells in culture. Cell. Motil. Cytoskeleton 38, 351-364.
55. Satyamoorthy, K., Muyrers, J., Meier, F., Patel, D., and Herlyn, M. (2001). Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication. Oncogene, 20, 4676-4684.
56. Schadendorf, D., Moller, A., Algermissen, B., Worm, M., Sticherling, M., and Czarnetzki, B.M. (1993). IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J. Immunol., 151, 2667-2675.
57. Scheibenbogen, C., Mohler, T., Haefele, J., Hunstein, W., and Keiholz, U. (1995). Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumor load. Melanoma. Res., 5, 179-181.
58. Sers, C., Kirsch, K., Rothbächer, U., Riethmüller, G., and Johnson, J.P. (1993). The gene encoding the melanoma-associated glycoprotein MUC18 displays a unique structure among the members of the immunoglobulin superfamily. Proc. Natl Acad. Sci. U S A 90, 8514-8518.
59. Shih, I.M. (1999). The role of CD146 (Mel-CAM) in biology and pathology. J. Pathol. 189, 4-11.
60. Shih, I.-M., Elder, D.E., and Herlyn, M. (1994a). Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. Am. J. Pathol. 145, 837-845.
61. Shih, I.M., Elder, D.E., Speicher, D., Johnson, J.P., and Herlyn, M. (1994b). Isolation and functional characterization of the A32 melanoma-associated antigen. Cancer Res. 54, 2514-2520.
62. Shih, I.M., Wang, T.L., and Westra, W.H. (1996). Diagnostic and biological implications of mel-CAM expression in mesenchymal neoplasms. Clin. Cancer. Res. 2, 569-575.
63. Shih, I.-M., Speicher, D.W., Hus, M.-Y., Levine, E., and Herlyn, M. (1997). Melanoma cell-cell interactions are mediated through heterophilic Mel-CAM/ligand adhesion. Cancer Res. 57, 3835-3840.
64. Shih, I.M., Nesbit, M., Herlyn, M., and Kurman, R.J. (1998). A new Mel-CAM (CD146)-specific monoclonal antibody, MN-4, on paraffin-embedded tissue. Mod. Pathol. 11, 1098-1106.
65. Singh, R.K., Gutman, M., Radinsky, R., Bucana, C.D., and Fidler, I.J. (1994). Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res. 54, 3242-3247.
66. Singh, R.K., Gutman, M., Reich, R., and Bar-Eli, M. (1995). Utraviolet-B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of interleukin-8. Cancer Res. 55, 3669-3674.
67. Singh, R.K., Varney, M.L., Bucana, C.D., and Johansson, S.L. (1999). Expression of interleukin-8 in primary and metastatic malignant melanoma of the skin. Melanoma Res. 9, 383-387.
68. Smith, D.R., Polverini, P.J., Kunkel, S.L., Orringer, M.B., Whyte, R.I., Burdick, M.D., Wilke, C.A., and Strieter, R.M. (1994). Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J. Exp. Med. 179, 1409-1415.
69. Sondak, V.K., Sabel, M.S., and Mule, J.J. (2006). Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Clin. Cancer Res. 12 (Suppl.), 2337s-2341s.
70. Strieter, R.M. (2001). Chemokines: not just leukocyte chemoattractants in the promotion of cancer. Nat. Immunol. 2, 285-286.
71. Sun, W., and Schuchter, L.M. (2001). Metastatic melanoma. Curr. Treat. Options. Oncol. 2, 193-202.
72. Tagawa, S.T., Cheung, E., Banta, W., Gee, C., and Weber, J.S. (2006). Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma. Cancer 106, 1353-1357.
73. Tellez, C., and Bar-Eli, M. (2003). Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene 22, 3130-3137.
74. Tellez, C., McCarty, M., Ruiz, M., and Bar-Eli, M. (2003). Loss of activator protein-2alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J. Biol. Chem. 278, 46632-46642.
75. Ugurel, S., Rappl, G., Tilgen, W., and Reinhold, U. (2001). Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J. Clin. Oncol. 19, 577-583.
76. Varney, M.L., Johansson, S.L., and Singh R.K. (2006). Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am. J. Clin. Pathol. 125, 209-216.
77. Weichert, W., Knosel, T., Bellach, J., Dietel, M., and Kristiansen, G. (2004). ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J. Clin. Pathol. 57, 1160-1164.
78. Westphal, J.R., Van't Hullenaar, R. et al. (2000). Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF, and angiostatin in relation to vascular density of xenografts in vivo. Int. J. Cancer 86, 768-776.
79. Xie, S., Luca, M., Huang, S., Gutman, M., Reich, R., Johnson, J.P., and Bar-Eli, M. (1997a). Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res. 57, 2295-2303.
80. Xie, S., Price, J.E., Luca, M., Jean, D., Ronai, Z., and Bar-Eli, M. (1997b). Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells. Oncogene, 15, 2069-2075.
81. Yoshida, S., Ono, M., Shono, T., Izumi, H., Ishibashi, T., Suzuki, H., and Kuwano, M. (1997). Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol. Cell Biol. 17, 4015-4023.